Printer Friendly

IMMUNOGEN, INC. NAMES ROBERT J. CONNAUGHTON, JR., GENERAL COUNSEL

 CAMBRIDGE, Mass., June 9 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the appointment of Robert J. Connaughton, Jr., as general counsel, a newly created position. From 1989 to the present, Connaughton was president and chief operating officer of BancIreland/First Financial, Inc., Boston. Before that, he was executive vice president and general counsel at First Financial.
 As president and chief operating officer at BancIreland/First Financial, Connaughton managed a 20-person bank subsidiary engaged in corporate finance, "big ticket" equipment leasing and project finance. He was responsible for the origination and closure of $350 million in financing transactions as well as numerous syndications. In 1987-88, as executive vice president and general counsel at First Financial, Connaughton negotiated and closed all of the company's transactions and reduced outside legal costs by $275,000 in the first year. From 1978-87, he was managing attorney for EG&G, Inc. Connaughton holds a J.D. from Suffolk University and a B.A. from the University of Prince Edward Island.
 "Bob Connaughton has 15 years' experience in the management of legal and financial affairs at major corporations. He is a valuable addition to the ImmunoGen team," states Donald J. McCarren, president and chief operating officer. "To fully exploit the value of our technology and to ensure the development of other technology platforms, we are making significant product development decisions and constructing a long-term, corporate strategic plan. As part of that plan, ImmunoGen is looking to begin the generation of near-term revenues in collaboration with third parties. Working in concert with Bob Tellis, ImmunoGen's vice president of corporate development, Bob Connaughton will help guide the expansion of these activities as we enter into new agreements and partnerships for product development and marketing."
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins and drugs conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first- generation products, the Oncolysins(R), are designed for use as post- remission consolidation therapy.
 -0- 6/9/93
 /CONTACT: Mark Ratner, director of external communications, ImmunoGen, 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU: PER

DJ -- NE003 -- 6867 06/09/93 08:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1993
Words:367
Previous Article:IMMUNOGEN, INC. NAMES JOHN A. KNOX DIRECTOR OF HUMAN RESOURCES
Next Article:GENETICS INSTITUTE, INC. TO REDEEM CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
Topics:


Related Articles
IMMUNOGEN EXPANDS MANAGEMENT TEAM: DONALD J. MCCARREN NAMED PRESIDENT AND CHIEF OPERATING OFFICER
IMMUNOGEN, INC. NAMES ROBERT E. TELLIS VICE PRESIDENT OF CORPORATE DEVELOPMENT
IMMUNOGEN ANNOUNCES RESIGNATION OF PRESIDENT DONALD J. McCARREN
IMMUNOGEN, INC., PROMOTES TWO IN RESEARCH AND DEVELOPMENT AND ANNOUNCES THE RESIGNATION OF ITS VICE PRESIDENT, CORPORATE DEVELOPMENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters